PreMD Receives CE Mark for New Handheld PREVU(x) Reader
August 01 2006 - 10:00AM
PR Newswire (US)
TORONTO, Aug. 1 /PRNewswire-FirstCall/ -- Predictive medicine
company PreMD Inc. (TSX: PMD; Amex: PME) today announced that its
second-generation spectrometer, or color reader, for the PREVU(x)
Point of Care (POC) Skin Sterol Test now has the Conformite
Europeene (CE) Mark. The CE Mark designation signifies that the new
reader conforms to the essential requirements of the European Union
Medical Devices Directive and validates the viability of the
product. "The CE Mark allows the new reader to be marketed in the
European Union," said Dr. Brent Norton, President and Chief
Executive Officer. "This standalone, portable reader is designed to
offer users greater flexibility, which we believe will enhance the
market appeal of PREVU(x) POC." The new reader was developed in
conjunction with Boehringer Ingelheim microParts GmbH and will be
manufactured in the United States by Jabil Circuit Inc. About
PREVU(x)POC Skin Sterol Test PREVU(x) non-invasively measures the
amount of cholesterol (sterol) that has accumulated in the skin
tissues, as opposed to blood. There is no fasting or other patient
preparation required for the test. Clinical studies have shown that
as cholesterol accumulates on artery walls it also accumulates in
other tissues, including the skin. High levels of skin sterol are
correlated with higher incidence of coronary artery disease (CAD).
PREVU(x) POC is cleared for sale in Canada, the U.S. and Europe
where it is available for sale to medical professionals. About
PreMD PreMD Inc. is a world leader in predictive medicine,
dedicated to developing rapid, non-invasive tests for the early
detection of life-threatening diseases. PreMD's cardiovascular
products, which are branded as PREVU(x) Skin Sterol Test, are
licensed worldwide to McNeil Consumer Healthcare. The company's
cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast
cancer test. PreMD's head office is located in Toronto, and its
research and product development facility is at McMaster University
in Hamilton, Ontario. For further information, please visit
http://www.premdinc.com/. For more information about PREVU(x),
please visit http://www.prevu.com/ or call 1-866-283-8328 (North
America) or 00-800-8283-8328 (Europe), or email . This press
release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties
include, among others, the successful development or marketing of
the Company's products, the competitiveness of the Company's
products if successfully commercialized, the lack of operating
profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies,
product liability, reliance on third-party manufacturers, the
ability of the Company to take advantage of business opportunities,
uncertainties related to the regulatory process, and general
changes in economic conditions. In addition, while the Company
routinely obtains patents for its products and technology, the
protection offered by the Company's patents and patent applications
may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain
patent protection for our products or product candidates. Investors
should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. PreMD is providing this information as
of the date of this press release and does not undertake any
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise. (x) Trademark DATASOURCE: PreMD Inc. CONTACT: Sarah
Borg-Olivier, Director, Communications, Tel: (416) 222-3449 ext.
27, Email:
Copyright